Hansa Biopharma AB (HNSA) — Cash Flow Reinvestment Rate
Latest as of September 2020:
3.23x
Hansa Biopharma AB (HNSA) has a Cash Flow Reinvestment Rate of 3.23x as of September 2020, reinvesting Skr15.60 Million (capex Skr683.00K plus investments Skr14.91 Million) from operating cash flow of Skr4.83 Million. See HNSA free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
3.23x
(Capex + Investments) / Operating CF
Total Reinvested
Skr15.60 Million
Capex + Investments
Operating Cash Flow
Skr4.83 Million
SEK
Capital Expenditures
Skr683.00K
SEK
Annual Cash Flow Reinvestment Rate for Hansa Biopharma AB (None–None)
Year-by-year capital reinvestment analysis for Hansa Biopharma AB. See financial agility of Hansa Biopharma AB to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (SEK) | Operating CF | Capex | YoY Change |
|---|
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow